2021+药师共识指南：类风湿关节炎患者生物制剂过渡的监测.pdfVIP

Original Research Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists Abstract Background: Recent approvals for novel agents such as the small molecule Janus kinase inhibitors (JAKi), combined with the advent of biosimilars has widened the gamut of available therapeutic options in the treatment of rheumatoid arthritis (RA). This combined with the introduction of mandatory non- medical switches to biosimilars in some jurisdictions by both public and private payors has led to a significant